These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

220 related items for PubMed ID: 7698284

  • 1. Inhibition of cholesterol synthesis ex vivo and in vivo by fluvastatin, a new inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase.
    Yamamoto A, Itoh S, Hoshi K, Ichihara K.
    Experientia; 1995 Mar 15; 51(3):223-6. PubMed ID: 7698284
    [Abstract] [Full Text] [Related]

  • 2. Species differences in the inhibiting effect of fluvastatin, a new inhibitor of HMG-CoA reductase, on cholesterol biosynthesis.
    Yamamoto A, Itoh S, Hoshi K, Ichihara K.
    Res Commun Mol Pathol Pharmacol; 1994 Dec 15; 86(3):325-34. PubMed ID: 7712108
    [Abstract] [Full Text] [Related]

  • 3. Selective inhibition of cholesterol synthesis in liver versus extrahepatic tissues by HMG-CoA reductase inhibitors.
    Parker RA, Clark RW, Sit SY, Lanier TL, Grosso RA, Wright JJ.
    J Lipid Res; 1990 Jul 15; 31(7):1271-82. PubMed ID: 2401858
    [Abstract] [Full Text] [Related]

  • 4. Tissue-selective inhibition of cholesterol synthesis in vivo by pravastatin sodium, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor.
    Koga T, Shimada Y, Kuroda M, Tsujita Y, Hasegawa K, Yamazaki M.
    Biochim Biophys Acta; 1990 Jul 16; 1045(2):115-20. PubMed ID: 2116173
    [Abstract] [Full Text] [Related]

  • 5. Effect of fluvastatin sodium (XU62-320), a new inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, on the induction of low-density lipoprotein receptor in HepG2 cells.
    Hayashi K, Kurokawa J, Nomura S, Kuga Y, Ohkura Y, Kajiyama G.
    Biochim Biophys Acta; 1993 Apr 07; 1167(2):223-5. PubMed ID: 8466953
    [Abstract] [Full Text] [Related]

  • 6. Tissue-selective acute effects of inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase on cholesterol biosynthesis in lens.
    Mosley ST, Kalinowski SS, Schafer BL, Tanaka RD.
    J Lipid Res; 1989 Sep 07; 30(9):1411-20. PubMed ID: 2513368
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Fluvastatin normalizes the decreased turnovers of glutathione and ascorbic acid in Watanabe heritable hyperlipidaemic rabbits.
    Suzumura K, Kasahara E, Ohnishi Y, Chien KC, Inoue M.
    Clin Exp Pharmacol Physiol; 2000 Sep 07; 27(9):709-14. PubMed ID: 10972538
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Inhibitory effect of fluvastatin on ileal ulcer formation in rats induced by nonsteroidal antiinflammatory drug.
    Hagiwara M, Kataoka K, Arimochi H, Kuwahara T, Nakayama H, Ohnishi Y.
    World J Gastroenterol; 2005 Feb 21; 11(7):1040-3. PubMed ID: 15742411
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Effect of 3-hydroxy-3-methylglutarylcoenzyme A reductase inhibitors (statins) on tissue paraoxonase 1 and plasma platelet activating factor acetylhydrolase activities.
    Bełtowski J, Wójcicka G, Jamroz A.
    J Cardiovasc Pharmacol; 2004 Jan 21; 43(1):121-7. PubMed ID: 14668577
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Hepatic and nonhepatic sterol synthesis and tissue distribution following administration of a liver selective HMG-CoA reductase inhibitor, CI-981: comparison with selected HMG-CoA reductase inhibitors.
    Bocan TM, Ferguson E, McNally W, Uhlendorf PD, Bak Mueller S, Dehart P, Sliskovic DR, Roth BD, Krause BR, Newton RS.
    Biochim Biophys Acta; 1992 Jan 24; 1123(2):133-44. PubMed ID: 1739744
    [Abstract] [Full Text] [Related]

  • 18. Relationship between mevalonate pathway and arterial myocyte proliferation: in vitro studies with inhibitors of HMG-CoA reductase.
    Corsini A, Mazzotti M, Raiteri M, Soma MR, Gabbiani G, Fumagalli R, Paoletti R.
    Atherosclerosis; 1993 Jun 24; 101(1):117-25. PubMed ID: 8216498
    [Abstract] [Full Text] [Related]

  • 19. Antioxidative potential of fluvastatin via the inhibition of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase activity.
    Bandoh T, Sato EF, Mitani H, Nakashima A, Hoshi K, Inoue M.
    Biol Pharm Bull; 2003 Jun 24; 26(6):818-22. PubMed ID: 12808293
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.